COPD is a disease characterized by airflow limitation. This
Apart from smoking cessation, no intervention has been shown to alter the decline in lung function in COPD, and current treatments limitation is not fully reversible and is usually both progressive are directed at relieving symptoms, reducing complications, and and associated with an abnormal inflammatory response of the improving the patient's quality of life. lungs to noxious particles or gases. [1] Typical symptoms are cough productive of sputum and breathlessness on exertion. Patients are In contrast to COPD, asthma affects all age groups, with also prone to infective exacerbation with worsening breathlessness highest prevalence among children. [6] [7] [8] It is characterized by variaand purulent sputum production. The most important etiological ble airflow, bronchial hyperresponsiveness, and eosinophilic inagent is tobacco smoking. [2, 3] COPD is rarely evident before flammation in the airways. Typical symptoms are cough and middle age [4] and prevalence continues to increase with age. [2, 5] shortness of breath with wheeze. Individuals with asthma are also prone to exacerbation with increasing symptoms. [6, 7] Unlike ing spirometry with reversibility, skin allergy testing, and serial COPD, current asthma treatments can have a dramatic effect on peak flow measurements. both morbidity and mortality.
Stage 1
Significant health and economic consequences accompany both diseases. In the US an estimated 15 million persons have been Population Sampling diagnosed with COPD, with as many as 16 million more thought to The Queen's University Belfast Research Ethics Committee be undiagnosed. [9] It is the fourth leading cause of death (resulting granted approval for the study. Eligible subjects were selected in more than 112 000 fatalities in 1998 [10] ) and is estimated to have from the general population in two areas in Northern Ireland: (i) resulted in $US6.6 billion in direct medical costs in 2000 [11] and North and West Belfast; (ii) North Down and Ards. These electoupwards of $US15.5 billion [12] in direct and indirect healthcare ral areas have a population of approximately 140 000 each, and costs in 1993. By comparison, in 1998 in the US an estimated 11.9 represent urban and semi-rural environments, respectively. Eligimillion persons had experienced an asthma attack in the past 12 ble subjects were Caucasian men and women aged 40-69 years months [13] (this being the criterion used to define active asthma) who were non-resident in an institution. A random sample of 4000 and 4269 patients died of the condition in the US in 2001. Direct individuals, 2000 from each area, were selected from the Master and indirect costs (including lost productivity) associated with the Patient Index of the Eastern Health and Social Services Board (the disease in the US were estimated at between $US6 billion [14] and health authority area in which these regions are located). This $US11 billion [15] in 1987 (both costs expressed in year 1994 database contains all those who have been registered with a dollars). Research in several other countries has reported similarly general practitioner within the health board area. In May 2000 a high rates of morbidity and cost associated with both diseasshort questionnaire, consisting of nine items including questions es. [16] [17] [18] [19] [20] [21] Studies have also shown cost of illness to increase with derived from the Medical Research Council (MRC) Respiratory disease severity in both asthma and COPD. [2, 20] Symptoms Questionnaire and the MRC Dyspnoea Scale, [25] was In the UK, two studies have examined the cost associated with sent by post and was self-administered. To maximize response, a managing COPD. [22, 23] These annual costs were estimated to be second mailing was sent to non-responders 6 weeks after the first £817.5 million (or £126 per patient) at year 1996/97 prices and mailing. Respondents were divided into 'symptomatic' and £819.42 at year 2000/01 prices. The former study was based on a 'asymptomatic' groups according to responses. 'Symptomatic' subgroup analysis of data collected in the years 1992/93 where was defined as positive for MRC Dyspnoea Scale grade 2 or COPD was identified using ICD-9 codes. As recognized by the higher. Of the 4000 individuals who were sent questionnaires, author, the study is likely to underestimate current costs because of 67% responded (n = 2484; 994 symptomatic and 1490 asymptomthe diagnostic uncertainty regarding COPD in the database used. atic). The latter study relied on a telephone survey, in which a self-reported diagnosis or the presence of symptoms or both were used to Stage 2 identify patients. Again, the basis of diagnosis is potentially problematic because no objective criteria were used to substantiate the Population Sampling diagnosis of COPD. In this study, we report the results of a Of positive respondents, 1330 (614 symptomatic and 716 comparison of the direct medical costs associated with COPD and asymptomatic) were randomly invited to allow a visit at home by asthma where diagnoses are based on a robust prevalence study of the respiratory nurse to perform the assessment. When an individa random sample from the Northern Ireland population.
[24] We ual was not contactable or refused a home visit, another patient focus on direct costs because these are of fundamental concern to was randomly selected from the appropriate group (380 individuhealthcare policy makers and because direct cost data are likely to als were not contactable due to absent phone company listing; 152 be captured more robustly.
with a phone listing were not contactable after four attempts; 25 had invalid spirometry; 47 refused to participate; 4 were deMaterials and Methods ceased). A home visit assessment was completed in 722 individuals (326 symptomatic, 396 asymptomatic; see figure 1 for further The survey was designed in two stages. In stage 1 a postal details). screening questionnaire concerning respiratory symptoms was Home Visit Assessment sent to a random sample of the general population. In stage 2, a sample of the respondents completed a detailed questionnaire on After written consent was obtained, patients completed a nonsymptoms, co-morbidities, and medication use as well as performvalidated questionnaire concerning symptoms and medical histo- ry, use of medication and health services, smoking history, occucontrol. Subjects were asked to complete the EuroQol((Author: please define)) questionnaire.
[27] pation, and social status. Height and weight were measured. Spirometry was performed with the Vitalograph ((Author: is this a Diagnoses trade name -please provide city and manufacturer)) 'Gold A physician reviewed data for each patient, and a clinical Standard' bellows device in accordance with the British Thoracic diagnosis was assigned. Possible diagnoses included 'asthma', Society (BTS) guidelines. Patients were asked to omit bronchodi-'COPD' and 'indeterminate airflow obstruction'. A diagnosis of lator inhalers for 12 hours prior to assessment. Baseline spirometry asthma required spirometric evidence of airflow obstruction with was taken as the best FEV1 and best FVC of three technically reversibility of FEV1 >15% following the administration of a β2-agonist, ± peak flow variability >15%, in the context of sympsatisfactory readings. The reference values established by Quanjer toms of attacks of wheezing associated with dyspnea, regular or et al. [26] were used. Airflow obstruction was defined as FEV1 /FVC nocturnal cough, or diurnal variation of symptoms. A diagnosis of ratio of <70%, with FEV1 <80% predicted. Reversibility to COPD required airflow obstruction on spirometry with reversibili-β2-adrenoceptor agonists (β2-agonists) was tested by repeating ty <15%, with peak flow variability <15%, in the context of a spirometry 15 minutes after inhalation of albuterol (salbutamol) smoking history and regular symptoms of dyspnea, cough and 400µg through a large volume spacer. Reversibility was defined as wheeze, which did not show diurnal variability. Patients with an increase in FEV1 >200mL and 15% greater than pre-bronchodiairflow obstruction and no reversibility who had symptoms suglator value. After adequate instruction, patients were asked to gesting asthma earlier in life were labeled as asthma rather than record serial peak flows morning and evening for 2 weeks. Skin COPD. After this review, 57 individuals had a diagnosis of asthprick allergy testing was performed using extracts of house dust ma, 49 a diagnosis of COPD, and 7 were labeled as 'indeterminate mite, cat, dog, grass mix and aspergillus, histamine, and a negative airflow obstruction'.
Detailed information relating to healthcare utilization in the past 12 months, the impact of the disease on the individual's overall quality of life, activities of daily life and socioeconomic conditions was elicited. Measures of healthcare utilization included details of medications, general practitioner visits, and hospital usage (outpatient and inpatient). Respondents were asked about healthcare utilization and healthcare accessed solely in relation to breathlessness. With regard to medications, respondents were asked to identify medications they regularly took as a result of breathlessness.
Healthcare costs were calculated using standard references, i.e. unit costs of health and social care [28] in respect of the various services utilized (e.g. general practitioner visits and hospital visits); the British National Formulary [29] was used in respect of prescribed medications. The same descriptive statistics were calculated regarding the various health services used.
Statistical Methods
Data are presented as mean with standard deviation and accom- panying range. None of the cost data variables were normally distributed, and most had median values of 0. Comparative analyDescriptive statistics on the various components of healthcare ses were performed using Mann Whitney U tests for costs for COPD and asthma patients are presented in table II. In nonparametric data. Correlations were tested using nonparametric each instance, average costs were higher among asthma patients methods (Kendall's Tau). The regression analyses were undertakthan among COPD patients. Significant differences in respect of en using various transformations of the dependent variable (total inhaler costs, all drug costs and total costs were observed. cost) and specifications of independent variables. Those presented A series of bivariate correlations between various components showed a square root transformation of total cost and linear of cost and patient characteristics are presented in table III. In versions of explanatory variables.
COPD patients, % predicted FEV 1 was significantly correlated with several aspects of cost, as was school years. As % predicted Results FEV1 fell, so general practitioner, drug and total costs tended to rise; as school years rose, so drug and total costs also fell. In An examination of cost data revealed the existence of three asthma patients, smoking status, years of schooling and EuroQol outliers within the asthma group One patient spent 90 days in score were significantly correlated with any of the measures of hospital compared with an average of 2.5 days, another reported cost. Smoking was positively correlated with hospital, general 50 general practitioner visits compared with an average of 6.33, practitioner and total costs; EuroQol score was negatively correlatand one patient accounted for all nursing auxiliary visits by asthma ed with hospital costs; and general practitioner costs and school patients. Inclusion of these three patients would in each instance years were negatively correlated with general practitioner costs. substantially raise the mean costs and they were therefore excluded from the analysis. Descriptive statistics on a range of patient
In table IV the results of a multivariate analysis of total costs characteristics for the two groups are presented in table I. COPD regressed on various patient characteristics for the two patient patients were more likely to be male and to have smoked in the groups are reported. To improve functional form, the total costs past. COPD patients also had significantly lower % predicted were transformed to their square root before running the regres-FEV1 consistent with a greater degree of airflow limitation. Desion. In the case of patients with COPD, while the percentage of spite lower lung function, EuroQol scores were higher in COPD the total variation in cost that is explained by the independent than asthma. With regard to prior physician diagnosis, 73.5% of variables may be small (r 2 = 0.34), the relationship is significant, patients with COPD had not been previously diagnosed compared as are two of the independent variables (% predicted FEV1 and with 15.8% of patients with asthma.
EuroQol score). Both these variables are negatively related to a Hospital costs represent the sum of accident and emergency, inpatient day and outpatient day costs.
b GP visit costs are the sum of both home and surgery visit costs.
c All patients were assumed to use oxygen concentrators rather than cylinders.
d All drug costs were defined as the sum of inhalers, nebulizers, systemic corticosteroid and nonsteroidal tablets (for airways disease), and oxygen costs.
e Total costs were defined as the sum of all drug costs, hospital and general practitioner (GP) visit costs.
overall costs. Alternative specifications of the model using current Discussion smoking patterns rather than 'ever having smoked' as independent The cost estimates in this study are based on a representative variables as well as logarithmic transformations of cost and % community-based sample in which the diagnoses of asthma and COPD have been well characterized and include asymptomatic predicted FEV1 were examined. While these marginally increased and undiagnosed individuals. Given that effective disease-modifythe explanatory power of the function with respect to patients with ing treatment is available for asthma and not COPD, it not surpris-COPD, conclusions remained unchanged (results not presented).
ing that less is spent on drug therapy for COPD across the In asthma patients the overall regression relationship was only spectrum of severity. It is accepted that a high proportion of the marginally significant, as indicated by the F-statistic being significost of COPD is incurred by those with severe disease, [30] who are cant only at the 90% level of confidence.
not well represented in this study. At present, smoking cessation is a One individual was omitted from the analysis as no data was recorded for this patient on ever having been a smoker.
b One individual was omitted from the analysis as no data was recorded for the number of school years this patient had completed. GP = general practitioner. * p < 0.01; ** p < 0.05;*** p < 0.01 the only known effective disease-modifying strategy in COPD, but sons (even adjusting for inflation) somewhat difficult. In relation to other estimates, Ward et al. [11] using year 1994 prices estimated much research is taking place developing new drugs for the total healthcare costs per year at $US6.6 billion for COPD in the treatment of COPD. The application of effective therapy for US. Given an estimated 15 million persons with COPD, [11] this disease progression could increase costs considerably in the short translates to an average annual cost per patient, in year 1994 term in the less severe categories of COPD. In addition, the prices, of $US440; i.e. $US502 in year 2000 prices assuming prevalence of COPD is likely to continue to increase as the inflation in healthcare prices of 14.1% between 1994 and 2000. population ages, which will have an impact on costs.
This compares with the $US309 (assuming an exchange rate of £1 Taking the two diseases separately, average annual costs per = $US1.80((Author: year 2000 value?))) estimated here. Howevpatient with COPD are generally lower in the present study than er, the Ward estimate included elements of cost not included here, have been reported elsewhere in the literature, ((Author: please such as nursing home stays (which were occasioned by some of his provide references)) though some care is warranted in making study participants) as well as aspects of cost-related co-morbidicomparisons. As noted above and recognized by Guest, [22] estities. mates of costs associated with COPD in the UK are likely to With respect to other studies the divergence is somewhat wider. exhibit downward bias due to higher unit costs, making compariHilleman et al., [12] for example, again in the US, estimated average costs per patient year among stage 1 COPD patients at $US1681 (year 1999 prices), or approximately $US1731 (year 2000 prices) assuming inflation of 3%. Confining the comparison solely to stage 1 patients in our sample, costs were approximately $US49 per year (cost estimates by Hilleman et al. [12] and Pelletier-Fleury et al. [21] for COPD patients with greater degrees of disease severity are not particularly meaningful for comparison given the very small numbers of patients with these degrees of disease severity in the present study). Again though, care is warranted given our exclusion of indirect costs((Author: sense? Please rework sentence for better clarity)). Sensitivity analyses where we relax our assumption regarding least cost use of oxygen therapy [27] narrow the gap between our cost estimate and those of Ward et al. [11] and Hilleman et al. [12] Thus, assuming cylinder use at ((Author: please indicate year of estimates)) £667.74 per annum per patient, rather than concentrator use at £312.40 per annum, gives a mean costs per patient per annum of £92.62 (standard deviation = : please confirm this entry is correct)) ), or direct costs fall, though the relationship is non-linear (around the $US167 (standard deviation = $453((Author: please confirm this level of average costs [£171] each percentage point increase in entry is correct))). Comparing estimates of oxygen therapy in this predicted FEV1 is associated with a fall in total costs of approxistudy with those of Britton, [23] they are seen to be considerably mately £9 [approximately $US16.20]. This finding is consistent lower than their estimate of £819 ((Author: mean costs per with that of others where treatment costs have similarly been seen patient per annum?)). In part this may be explained by differto increase with disease severity [11, 21] and with intuition((Author: ences in the sample populations recruited, with Britton, for examwhat exactly do you mean by intuition)). In asthma no signifiple, selecting an older group of individuals with more severe cant relationship was found between treatment cost and disease disease (26.5% being rated as having severe and 45% moderate severity as determined by FEV1; however, the lower overall COPD). In addition, the assumptions used by the latter((Author: explanatory((Author: please confirm the word 'explanatory' is Britton?))in estimating costs may also play a role. For instance, appropriate here)) power of the model used in this study and its the consumption of a particular service at a specific level is marginal overall significance (as evidenced by the lower F-statisassumed to accompany the reported consumption of other sertic) must be taken into account. vices. Conclusion In the case of asthma, costs per patient in the US were estimated by Smith et al. [14] in year 1994 dollars at approximately $US1302, This main strengths of this study are its community base of based on an affected adult population of 2.7 million. Assuming patients and the accuracy of diagnosis of asthma and COPD. In inflation at 3.5% per annum over the intervening period, this this setting, asthma costs more than COPD, which may relate in translates to a cost per person in year 2000 dollars of approximatepart to a relative under-diagnosis of COPD. As anticipated, the ly $US1600. Assuming again an exchange rate of £1 = $US1.80, cost of COPD increases as FEV1 decreases but costs of asthma are our estimate translates to approximately $US998 per patient. The not predicted by FEV1. We were able to explain one-third of the estimate from Mellis et al. [18] of $US769 ((Author: please concosts of COPD and a quarter of the costs of asthma. The database firm this is $US and not $Aus)) per person in New South Wales, will enable modeling of the cost consequences of disease-modifyAustralia, in 1989 translates to a cost in year 2000 dollars of ing interventions such as smoking cessation programs, and in-$US1123, though they concede this may be an underestimate; creased diagnosis and better management of COPD. estimates by Unger et al. [30] in Canada of $US1275((Author: please confirm this is $US and not $Can)) per year in direct costs
£251.59((Author

